Diabetic Euglycemic Ketoacidosis Induced by Oral Antidiabetics Type SGLT2i.

Autor:	Velasco de Cos G; Hospital Universitario Marqués de Valdecilla, Santander, Spain., Sánchez-Molina Acosta MI; Hospital Comarcal de Laredo, Spain., Fernández MMT; Hospital Universitario Marqués de Valdecilla, Santander, Spain.
Jazyk:	angličtina
Zdroj:	EJIFCC [EJIFCC] 2021 Feb 28; Vol. 32 (1), pp. 105-110. Date of Electronic Publication: 2021 Feb 28 (Print Publication: 2021).
Abstrakt:	Euglycemic diabetic ketoacidosis (euglycemic DKA) is a serious complication of diabetes, which can occur in some patients treated with oral antidiabetics called sodium-glucose co-transporter 2 inhibitors (SGLT2i). This group of drugs works by increasing renal excretion of sodium and glucose, thereby lowering blood glucose levels. Euglycemic DKA is characterized by having blood glucose levels in the normal range, usually below 200 mg/dL (11 mmol/L), which complicates early diagnosis. We present the case of a 67-year-old patient with type 2 diabetes mellitus, treated with metformin and empagliflozin, who was admitted to the Intensive Care Unit in a coma with severe ketoacidotic decompensation. Competing Interests: All authors confirmed they have contributed significantly to the analysis and interpretation of data, revising, and approving the article. All authors declare no conflicts of interest. (Copyright © 2021 International Federation of Clinical Chemistry and Laboratory Medicine (IFCC). All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu